Edwards Lifesciences Cvp, Tavr Daniel J. Lippis Sells $64.5K of Stock
Daniel J. Lippis, Cvp, Tavr, sold 619 shares of Edwards Lifesciences Corp at $104.25 a share, worth $64.5K in total on Nov 10, 2026. Shares held after the trade: 40,034 (-1.5%).
Edwards Lifesciences CVP,Strategy/Corp Development Donald E. Bobo Jr. Sells $5.04M of Stock
Donald E. Bobo Jr., CVP,Strategy/Corp Development, sold 48,900 shares of Edwards Lifesciences Corp at $103.05 a share, worth $5.04M in total on Nov 9, 2026. Shares held after the trade: 22,798 (-68.2%).
Edwards Lifesciences CEO Bernard J. Zovighian Sells $2.38M of Stock
Bernard J. Zovighian, CEO, sold 23,100 shares of Edwards Lifesciences Corp at $102.78 to $103.39 a share (average $103.02) in 2 transactions, worth $2.38M in total on Nov 9, 2026. Shares held after the trade: 98,845 (-12.3%).
For the nine months ended September 30, 2026, Edwards Lifesciences reported net sales of $5.11 billion, a 13.5% increase over the prior year. Despite higher revenue, net income attributable to the corporation decreased to $930.1 million from $982.3 million, primarily due to a significant $163.6 million impairment loss and higher income tax provisions.
Edwards Lifesciences reported third-quarter 2026 sales of $1.72 billion, representing 11.2% constant currency growth driven by strong performance in TAVR and TMTT segments. Based on the results, the company raised its full-year 2026 sales growth guidance to approximately 11.5% and adjusted EPS guidance to $2.97-$3.05.
Term
3 years
“We delivered strong third-quarter growth of 11.2% which exceeded expectations, with broad-based performance across our businesses and regions, giving us the confidence to raise our full-year outlook.”